Life Transitions

Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.

What the obstetrician-gynecologist should know

A literature review found that although hormonal therapy with estrogen is the first-line therapy for bothersome vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM) symptoms, nonhormonal medications such as paroxetine and venlafaxine can also be effective for VMS.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.

A new study offers insights into future guidelines for certain populations of pregnant women during a national pandemic.

Investigators identify a strong association between exposure to air pollution and bone mineral loss in postmenopausal women.

Further adding to the discussion surrounding the impact of endocrine-disrupting chemicals, an analysis of data from the SWAN Multipollutant Study suggests increased exposure to phthlates was linked to a 30-63% increase in risk of developing diabetes among White women in midlife.

The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.

Research reveals that hormone therapy and alternative medicine do not enhance quality of life for midlife women experiencing menopause symptoms.

An analysis of data from the China Kadoorie Biobank study suggests cumulative exposure to estrogen was associated with stroke risk in postmenopausal women.

A recent study analyzed the effect artificially sweetened beverages have on urinary incontinence in women.

Rebecca Thurston, PhD, sits down to discuss her research presented at the NAMS Annual Meeting on vasomotor symptoms and cardiovascular health.

Rebecca Thurston, PhD, sits down to discuss the latest news from the North American Menopause Society Annual Meeting.

Research in Menopause connects history of physical/sexual abuse, financial instability with worse menopausal symptoms and overall wellbeing at midlife.

History of migraine may be associated with poor sleep in premenopausal and perimenopausal women, according to research presented at the North American Menopause Society Annual Meeting.

Traumatic experiences are associated with lower levels of sex hormones in midlife women, especially those with short sleep, according to research presented at the North American Menopause Society Annual Meeting.

A presentation at the North American Menopause Society Annual Meeting outlined the approval status and effectiveness of various pharmacologic treatments of vasomotor symptoms.

In a presentation at the North American Menopause Society Annual Meeting, a study found that women may be more inclined to gain weight during the menopause transition.

Women with diabetes are more susceptible to early menopause, according to a study presented at the North American Menopause Society Annual Meeting.

Hormone therapy was linked as a potential preventative treatment for adhesive capsulitis in menopausal women, according to a study presented at the North American Menopause Society Annual Meeting.

In a presentation at the North American Menopause Society Annual Meeting, investigators found these signs of menopause are 2 very separate symptoms and have different effects on stress and depression in menopausal women.

More women are using medical cannabis for menopause-related symptoms, according to research recently published in Menopause.

The Women’s Preventive Services Initiative (WPSI) has released a new clinical guideline outlining their recommendations for preventing obesity among women in midlife.

Genevieve Neal-Perry, MD, PhD, sits down with Contemporary OB/GYN to discuss positive data from a recent phase 3 study evaluating fezolinetant (Astellas) for vasomotor symptoms (VMS).